Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06357832 · ClinicalTrials.gov registry record · NA
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
A NA study, sponsored by Brainsway.
- Completed
- Registry status
- NA
- Development phase
- 104
- Enrollment target
NCT06357832: Completed NA study, sponsored by Brainsway.
NCT06357832 is a NA study that has completed, run by Brainsway. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06357832, a NA study, has completed, sponsored by Brainsway.
- COMPLETED
- Registry status
- NA
- Development phase
- 104 participants
- Enrollment target
Study Summary
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency. The purpose of the current study is to evaluate the safety and effectiveness of a new investigational stimulation protocol delivered with the BrainsWay Deep TMS device, for the treatment of MDD, demonstrating that it is non-inferior to the current standard-of-care stimulation protocol, in a randomized, controlled study.
Primary Outcome
Change in Hamilton Depression Rating Scale (HDRS)-21 scores from baseline to the 6 week follow up
Interventions
- DEVICE Brainsway Deep TMS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2026-03-05 |
| Phase | NA |
What the finished NCT06357832 record still lists
NCT06357832 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Brainsway Deep TMS System is the first listed.
NCT06357832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06357832 about?
NCT06357832 is a clinical study titled "New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)". The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determi...
What is the current status of trial NCT06357832?
This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2024-04-29. Estimated completion is 2026-03-05.
What interventions are being tested in trial NCT06357832?
The interventions under investigation include: Brainsway Deep TMS System (DEVICE).
Who is sponsoring clinical trial NCT06357832?
This trial is sponsored by Brainsway, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06357832's enrollment target sits among peer trials
104 836th of 2000 higher than 1,164 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI